-
Reminder on risk of serious and fatal toxicity in overdose.
-
A certification mark has been designed and launched as an additional visible symbol.
-
All patients with cancer should have a dental check-up before bisphosphonate treatment.
-
Mixing drugs together, where one is not a vehicle for the administration of the other, creates an unlicensed medicine.
-
Patients who require a liquid oral formulation of a β-agonist should be switched to a more-selective short-acting β2-agonist such as salbutamol or terbutaline.
-
There is no known interaction between oseltamivir and aspirin but aspirin must not be given to anyone younger than 16 year.
-
If new movement disorders occur during treatment consider dose reduction or a gradual discontinuation of treatment in consultation with specialist advice.
-
Healthcare professionals should be aware of the updated information so they can discuss it with new and existing patients.
-
Updated advice for healthcare professionals not to mix or infuse ceftriaxone with solutions containing calcium.
-
Doses of theophylline, fluvoxamine, caffeine, coumarins including warfarin and the antipsychotics clozapine and olanzapine may have to be altered.
-
The human papillomavirus (HPV) immunisation programme is now entering its second year and this article summarises the safety experience to date.
-
The study found no clear evidence that varenicline was associated with an increased risk of fatal or non-fatal self-harm.
-
Patients with existing meningioma or a history of meningioma must not be prescribed high-dose (≥25 mg per day) cyproterone acetate.
-
The tighter controls being introduced to minimise risk of overuse and or addiction of painkillers containing codeine or dihydrocodeine.
-
The European Medicines Agency has advised that no change in recommendations for use is required at present.
-
How to reduce risk of illicit use.
-
How MHRA monitors the impact of regulatory action taken.
-
Important to inquire if patients are taking herbal medicines.
-
Cold-chain storage and distribution system now been fully implemented by manufacturer.
-
Use of has led to serious paracetamol overdose in a 6-month-old infant.
-
Overall benefits of long-acting β-agonists (LABAs) in the treatment of chronic obstructive pulmonary disease (COPD) continue to outweigh any risks.
-
Use during breastfeeding
-
Healthcare professionals should consider a dose reduction or discontinuation of mycophenolate mofetil if patients develop pure red cell aplasia.
-
Abacavir should be used in line with current treatment guidelines and with caution in patients with high cardiovascular risk factors.
-
A reminder for those who use topical ketoprofen to avoid direct sunlight, ultraviolet rays, sunbeds or sunlamps.
-
New safety information for intensive monitoring of Erlotinib.
-
Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers.
-
How pharmacists can prevent counterfeits reaching patients.
-
Continued monitoring of medicines with a black triangle status.
-
Use of Antipsychotic may be associated with an increased risk of venous thromboembolic events.
-
These medicines are not first-line options for insomnia.
-
You should take caution when you use NSAIDs in patients with renal impairment or are at risk.
-
Use of aliskiren can cause angioedema, a rare and serious side effect, and or acute renal failure.
-
Mothers who are breastfeeding should not take ACE inhibitors or angiotensin II receptor antagonists in the first few weeks after delivery.
-
Data suggests that long-term use of carbamazepine, phenytoin, primidone, and sodium valproate is associated with decreased bone mineral density that may lead to osteopenia, osteoporosis, and increased fractures.
-
High intravenous doses of methylthioninium chloride (methylene blue) should be avoided for patients being treated with serotonergic antidepressants (eg, SSRIs, clomipramine, and venlafaxine).
-
Healthcare professionals may have more responsibility to accurately prescribe an unlicensed medicine or an off-label medicine than when they prescribe a medicine within the terms of its licence.
-
Advice on how to use cough and cold medicines safely for children under 12 years.
-
Updated guidance to use methylphenidateto safely and effectively for attention deficit hyperactivity disorder (ADHD) in children of 6 years or older and adolescents.
-
Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.
-
There have been reports of necrotising and haemorrhagic pancreatitis in people taking exenatide some of which were fatal - stop exenatide treatment if pancreatitis is diagnosed.
-
Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents - consider stopping this if symptoms occur.
-
In 2008 MHRA commissioned Ipsos MORI to research the public’s perception of herbal medicines, the findings may help doctors and pharmacists when considering how to advise patients.
-
Toremifene (fareston) is associated with a dose-dependent risk of QT prolongation.
-
Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with tazocin, raising a risk of serious medication errors.
-
Severe infusion-related hypersensitivity reactions have occurred in patients receiving temsirolimus.
-
The European Medicines Agency (EMA) has concluded that oral fluoroquinolone norfloxacin (Utinor) shouldn't be used to treat acute or chronic, complicated pyelonephritis.
-
Toxic effects can occur with nitrous oxide especially with prolonged use.
-
New warnings and contraindications for ergot-derived dopamine agonists due to risk of fibrosis associated with chronic use.
-
Use the central alerting system to view and search new alerts, as well as past alerts that were issued through the public health link and safety alert broadcast system.